whi p154 has been researched along with T-Cell Lymphoma in 2 studies
WHI P154: an anti-leukemic agent; structure in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marzec, M | 2 |
| Kasprzycka, M | 2 |
| Ptasznik, A | 1 |
| Wlodarski, P | 2 |
| Zhang, Q | 1 |
| Odum, N | 1 |
| Wasik, MA | 2 |
| Liu, X | 1 |
| El-Salem, M | 1 |
| Halasa, K | 1 |
| Raghunath, PN | 1 |
| Bucki, R | 1 |
2 other studies available for whi p154 and T-Cell Lymphoma
| Article | Year |
|---|---|
Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.
Topics: Anaplastic Lymphoma Kinase; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose | 2005 |
Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Topics: Anaplastic Lymphoma Kinase; Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferat | 2007 |